RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0039-1695016
Delayed Cerebral Metastasis of Breast Cancer: Case Report and Molecular Review
Mestástase cerebral tardia de cancêr de mama: Relato de caso e revisão molecularPublikationsverlauf
07. März 2019
27. Mai 2019
Publikationsdatum:
27. August 2019 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00028832/201904/lookinside/thumbnails/10-1055-s-0039-1695016_1900018-1.jpg)
Abstract
Breast cancer (BC) is a prevalent disease, and its incidence of brain metastasis (BM) varies from 5 to 30% according to the literature. We present the case of a delayed isolated cerebral metastasis in a female patient following a period of 16 years after the diagnosis and first treatment. During this time, there was no other recurrence. We also review the literature concerning central nervous system spread and the molecular subtypes of such late tumors.
Resumo
O câncer de mama é uma doença prevalente e sua incidência de metástase cerebral varia de 5 a 30%, de acordo com a literatura. Apresentamos um caso de metástase cerebral tardia isolada em uma paciente do sexo feminino após um período de 16 anos do diagnóstico e tratamento. Durante esse período, não houve outra recorrência. Também é feita uma breve revisão da literatura sobre metástases de câncer de mama no sistema nervoso central e suas características moleculares.
-
References
- 1 Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94 (10) 2698-2705
- 2 Pestalozzi BC, Zahrieh D, Price KN. , et al; International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17 (06) 935-944
- 3 Altundag K, Bondy ML, Mirza NQ. , et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110 (12) 2640-2647
- 4 Yamada SM, Tomita Y, Shibui S, Kurokawa T, Baba Y. A Case of Breast Cancer Brain Metastasis with a 16-Year Time Interval without Evidence of Cancer Recurrence. J Breast Cancer 2017; 20 (02) 212-216
- 5 http://www.inca.gov.br – Instituto Nacional de Câncer, Brasil
- 6 Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol 2016; 127 (03) 407-414
- 7 Shen Q, Sahin AA, Hess KR. , et al. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist 2015; 20 (05) 466-473
- 8 Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13 (06) 1648-1655
- 9 Hung M-H, Liu C-Y, Shiau C-Y. , et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One 2014; 9 (02) e89389
- 10 Dayan A, Koca D, Akman T, Oztop I, Ellidokuz H, Yilmaz U. The factors that have an impact on the development of brain metastasis in the patients with breast cancer. J Cancer Res Ther 2012; 8 (04) 542-548
- 11 Ogawa K, Yoshii Y, Nishimaki T. , et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 2008; 86 (02) 231-238
- 12 Leone JP, Lee AV, Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med 2015; 4 (07) 989-994